| TRACK 1: R&D / Disease Linkages |
| How can biotech bridge the global health innovation gap? A focus on drug discovery for key neglected diseases |
- Moderator:
John Maraganore, CEO, Alnylam Pharmaceuticals
- Michael C. Venuti, PhD, CEO, BioSeek, Inc.
- John W. Erickson, PhD, CSO, Sequoia Pharmaceuticals
- Solomon Nwaka, PhD, Manager, Genomic and Discovery Research, Special Program for Research and Training in Tropical Diseases, WHO
- David P. Perry, CEO, Anacor Pharmaceuticals
|
| Needs and Opportunities in Diagnostics: Creating Sustainable Solutions for the Developing World |
- Moderator:
Jan Gheuens, MD, PhD, Senior Program Officer, Global Health Technologies, Bill & Melinda Gates Foundation
- Gary M. Cohen, President, BD Medical, BD
- Jenny Harry, PhD, BSc, CEO and Managing Director, Proteome Systems
- Jean-Francois de Lavison, Corporate VP, Global Health and International Affairs, Merieux Alliance
- Lawrence A. Siebert, President and CEO, Chembio Diagnostics, Inc.
- Karen Hedine, President and CEO, Micronics
|
| Building the R&D Capabilities within Developing Countries |
- Moderator:
Yves Champey, MD, Founding Chairman, Drugs for Neglected Diseases Initiative
- Fernando Kreutz, MD, PhD, Founder and CEO, FK Biotec
- Rashmi Barbhaiya, PhD, CEO and Managing Director, Advinus Therapeutics
- Paolo Meoni, PhD, Drug Development Manager, CSIR Biosciences
- Sarah E. Frew, PhD, McLaughlin-Rotman Center for Public Health, University Health Network/University of Toronto
|
| TRACK 2: Partnering / Business Models |
| Co-Development and Partnerships with Emerging Market Manufacturers: Advantages, opportunities and models |
- Moderator:
Peter Singer, MD, MPH, FRCPC, FRSC, Senior Scientist and Professor of Medicine, McLaughlin-Rotman Center for Public Health, University Health Network/University of Toronto
- Luca Guerzoni, CEO, Cambridge BioStability
- Jean-Francois de Lavison, Corporate VP, Global Health and International Affairs, Merieux Alliance
- Rajiv Malik, Senior Vice President, Advinus Therapeutics
|
| Ensuring Access: New Approaches to IP |
- Moderator:
Jeffrey P. Kushan, Sidley Austin, Partner, LLP
- Clifford M. Samuel, Senior Director, International Access Operations, Gilead Sciences
- Mark B. Feinberg, MD, PhD, Vice President, Policy, Public Health and Medical Affairs, Merck Vaccines
- Erik H. Iverson, Associate General Counsel, Bill & Melinda Gates Foundation
- Zeda Rosenberg, President and CEO, International Partnership for Microbicides
|
| New Models of Industry Collaboration |
- Moderator:
Robert Hecht, PhD, Senior VP, Public Policy, International AIDS Vaccine Initiative
- Joshua Boger, PhD, President and CEO, Vertex Pharmaceuticals
- Robert J. Beall, PhD, President and CEO, Cystic Fibrosis Foundation Therapeutics
- R. Lee Douglas, Consultant and Visiting Scholar, UC Berkeley
- James A. Geraghty, Senior Vice President, Genzyme Corporation
- Alan Taggart, Vice President, Government Project Management, MedImmune, Inc.
- Yves J. Ribeill, PhD, President and CEO, Scynexis (invited)
|
| Partnership Lessons and Stories from the Trenches |
- Moderator:
Ruth Levine, PhD, Senior Fellow and VP for Programs and Operations, Center for Global Development
- Melinda Moree, PhD, Former Director, PATH’s Malaria Vaccine Initiative
- Alan Shaw, PhD, President and CEO, VaxInnate, Inc.
- Mel Spigelman, MD, Director, R&D, Global Alliance for TB Drug Development
- Kate Taylor, MBBS, MPH, Vice President, Market Access, GlaxoSmithKline Biologicals
|
| TRACK 3: Markets / Incentives |
| Priority Review Vouchers: How much are they worth to global health? |
- Moderator:
J. Leighton Read, MD, General Partner, Alloy Ventures
- Timothy R. Cote, MD, MPH; Director, Office of Orphan Product Development; US Food and Drug Administration
- Diana M. Lanchoney, MD, Executive Director, Developing World Strategic Integration, Merck Vaccines and Infectious Diseases
- Henry G. Grabowski, PhD, Director, Program in Pharmaceuticals and Health Economics, Duke University Fuqua School of Business
- Nancy L. Buc, Partner, Buc & Beardsley
|
| Bridging Innovation and Access: Policy's Contribution to Global Health |
- Moderator:
Gregory M. Weinhoff, MD, Partner, CHL Medical Partners
- Alice Albright, CFO, GAVI Alliance
- Saul Walker, Senior Access to Medicines Policy Advisor, Health Services Team, UK Department for International Development
- Clement Lewin, PhD, VP, Marketing, Policy and Strategy, Acambis
- Robert B. Chess, Chairman, Nektar Therapeutics
- Hannah E. Kettler, PhD, Program Officer, Global Health Initiatives, Bill & Melinda Gates Foundation
|
| Uncovering Viable Markets for Global Health |
- Moderator:
Wendy Taylor, VP, Strategy and Operations, BIO Ventures for Global Health
- Jeffrey Hackman, VP, Marketing, Emergent BioSolutions
- Kate Taylor, MBBS, MPH, Vice President, Market Access, GlaxoSmithKline Biologicals
- William Greene, MD, General Partner, MPM Capital
- Thierry Darcis, MD, VP and General Manager, ViroPharma Europe
|
